Improved survival with MEK inhibition in BRAF-mutated melanoma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F12%3A00103101" target="_blank" >RIV/00843989:_____/12:00103101 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1203421" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1203421</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1203421" target="_blank" >10.1056/NEJMoa1203421</a>

Result language
angličtina
Original language name
Improved survival with MEK inhibition in BRAF-mutated melanoma
Original language description
Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previoustrials, MEK inhibition appeared to be promising in this population. In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2: 1 ratio. Patients received trametinib (2 mg orally) once daily or intravenous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 weeks. Patients in the chemotherapygroup who had disease progression were permitted to cross over to receive trametinib. Progression-free survival was the primary end point, and overall survival was a secondary end point. Median progression-free survival was 4.8 months in
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)